No pharmaceutical drug-drug- interaction studies have been conducted

Drug/lab test interactions-  admin of naferalin acetate in therapeutic doses results in suppression of
the pitutiary -gondal system. Normal function is restored within 4 to 8 weeks after treatment

Adverse reactions-  as the drug lowers serum estrodiol levels the most frequently reported
adverse reactions were those related to  hypoestrogenism

Less than 1% experienced

parathesia,    palpitations,     chloasma,     maculopapular rash,     eye pain,
asthenia,    lactation,     breast engrogement    and arthalgia

Hypersensitivity to any of the exceipients

Special Precautions-

Central Precocious Puberty- the diagnosis of central precocious puberty ( CPP ) must be
established before treatment.
Regular monitoring of CPP patients is needed to assess both patient response and compliance.
This is particularly important during the first 6 to 8 weeks of treatment to ensure that suppression
of pitutary -gonadal function is rapid

Ovarian cysts- as with other drug that stimulate the release of gonodotropins or that induce ovulation.
ovarian cysts have been reported to occur in the first two months of therapy with nefarin acetate 
These cysts enlargements may resolve spontaneously generally by about 4 to 6 weeks of therapy,
but in some cases may require discontiuation of the drug and/or surgical intervention

Pregnancy- before starting treatment, pregnancy must be excluded

Lactation- naferalin acetate should not used in nursing mothers.

Children- safety and efficacy of naferalin acetate for endometriosis in patients younger than
18 years have not been established

Indication-

Endometriosis

Dosage-
Endometriosis- recommended dose of naferalin acetate is 400mcg.
This is acheived by one spray ( 200mcg ) in one nostril in the morning and into the other
nostril in the evening
Treatment should be started between days 2 and 4 of the menstrual cycle.

Pregnancy-
Before starting treatment, pregnancy must be excluded

Lactation-
Naferalin acetate should not used in nursing mothers.

Children-
Safety and efficacy of naferalin acetate for endometriosis in patients younger than
18 years have not been established